A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes.

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2014

At a glance

  • Drugs Letaxaban (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
  • Focus Adverse reactions
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 21 Apr 2012 Planned number of patients changed from 2250 to 2750 as reported by EudraCT.
    • 31 Aug 2011 Results presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
    • 26 Oct 2010 Top-line results reported in a Takeda media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top